This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database.
All Wales Medicines Strategy Group (AWMSG). Quetiapine prolonged-release tablets (Seroquel XL®) for the treatment of schizophrenia in adults. Penarth: All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG). AWMSG Secretariat Assessment Report Advice No. 1509. 2009
Quetiapine prolonged-release tablets (Seroquel XL®) are recommended as an option for use within NHS Wales for the treatment of schizophrenia in adults.
In order to limit errors, prolonged-release quetiapine should be prescribed by brand name, as Seroquel XL®.
AWMSG is of the opinion that quetiapine prolonged-release tablets (Seroquel XL®) may be suitable for shared care within NHS Wales.
Quetiapine prolonged-release tablets (Seroquel XL®) are not endorsed for the treatment of manic episodes associated with bipolar disorder within NHS Wales. AstraZeneca UK Ltd is not in a position to progress a submission to AWMSG for its appraisal in this indication. As a result, AWMSG cannot provide advice to the Minister for Health and Social Services.
Subject indexing assigned by CRD
Adult; Aged; Antipsychotic Agents; Dibenzothiazepines; Middle Aged; Schizophrenias
Country of organisation
An English language summary is available.
Address for correspondence
All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road,
Penarth, Vale of Glamorgan CF64 2XX
Date abstract record published